Latest Breaking News On - Crinetics pharmaceuticals price performance - Page 5 : comparemela.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) – Investment analysts at SVB Leerink lowered their Q1 2023 earnings per share estimates for Crinetics Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 1st. SVB Leerink analyst J. Schwartz now forecasts that the company will post earnings of ($0.83) per share for […]

Stephenf betzMetlife investment managementBlackrock incCrinetics pharmaceuticals incHedge funds weigh in on crinetics pharmaceuticalsJpmorgan chase coGroup one tradingNews ratings for crinetics pharmaceuticals dailyCrinetics pharmaceuticals price performanceCrinetics pharmaceuticalsGet ratingCrinetics pharmaceuticalLife investment managementCrinetics pharmaceuticals dailyNasdaq crnxEarnings estimates